 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | RX108 / Suzhou NeuPharma
New P1 trial, Metastases: Phase I study to evaluate Safety and Tolerability of RX108-A Tablets in Patients with advanced Cancer (EUDRACT) - Sep 1, 2023
P1, N=20, Recruiting, Sponsor: NeuPharma Pty Ltd
- | RX108 / Suzhou NeuPharma
Enrollment open, Trial initiation date, Metastases: Phase I study to evaluate Safety and Tolerability of RX108-A Tablets in Patients with advanced Cancer (EUDRACT) - Sep 1, 2023
P1, N=20, Recruiting, Sponsor: NeuPharma Pty Ltd
Not yet recruiting --> Recruiting
- | RX108 / Suzhou NeuPharma
Journal: Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma. (Pubmed Central) - Feb 13, 2023
Taken together, these findings reveal a novel approach to target glutamine metabolism through inhibiting Na+/K+-ATPase and provide a rationale for using RX108 to treat HCC in patients whose tumors express ASCT2 at high levels. RX108 is currently under clinical development.
- || RX108 / Suzhou NeuPharma
Trial completion date, Trial primary completion date, Metastases: A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Apr 13, 2022
P1, N=80, Recruiting, Sponsor: NeuPharma, Inc.
RX108 is currently under clinical development. Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Aug 2021 --> Aug 2023
- || RX108 / Suzhou NeuPharma
Trial completion date, Trial primary completion date, Metastases: A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Oct 5, 2020
P1, N=80, Recruiting, Sponsor: NeuPharma, Inc.
Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Aug 2021 --> Aug 2023 Trial completion date: Sep 2020 --> Dec 2021 | Trial primary completion date: Mar 2020 --> Aug 2021
- | RX108 / Suzhou NeuPharma
New P1 trial, Metastases: A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Aug 23, 2018
P1, N=80, Recruiting, Sponsor: NeuPharma, Inc.